Alzheimer’s New Drugs: Who Will Benefit?
- Recent advancements in Alzheimer's disease treatment are generating optimism, but questions remain about who will be able to benefit from these new therapies and at what cost.
- The focus is on a new class of drugs called monoclonal antibodies, specifically lecanemab (Leqembi), approved by the U.S.
- Unlike previous treatments that primarily addressed symptoms, these medications attempt to modify the disease itself. However, they are not a cure and are most effective in the early...
“`html
New Alzheimer’s Drugs Offer Hope, But Access Remains a Key Question
Table of Contents
Recent advancements in Alzheimer’s disease treatment are generating optimism, but questions remain about who will be able to benefit from these new therapies and at what cost. This article synthesizes reporting from Corriere della Sera and broader coverage to provide a thorough overview of the situation as of September 22, 2024.
Last Updated: September 22, 2024, 11:26 AM PDT
What are the New Alzheimer’s Drugs?
The focus is on a new class of drugs called monoclonal antibodies, specifically lecanemab (Leqembi), approved by the U.S. Food and Drug Governance (FDA) in January 2023, and donanemab (Elysee), which received full FDA approval in June 2024. These drugs aim to slow the progression of Alzheimer’s disease by targeting and removing amyloid plaques, a hallmark of the disease, from the brain.
Unlike previous treatments that primarily addressed symptoms, these medications attempt to modify the disease itself. However, they are not a cure and are most effective in the early stages of Alzheimer’s, specifically mild cognitive impairment or early-stage dementia, with confirmed presence of amyloid plaques.
How Do Lecanemab and Donanemab Work?
Both lecanemab and donanemab are administered intravenously, requiring regular infusions. The Alzheimer’s Association explains that these antibodies bind to diffrent forms of amyloid beta, facilitating their removal by the body’s immune system. Clinical trials have demonstrated a modest slowing of cognitive decline – approximately 27% with lecanemab and 35% with donanemab – compared to placebo over 18 months.
It’s crucial to note that these drugs carry risks. A significant side effect is amyloid-related imaging abnormalities (ARIA), which can cause brain swelling or bleeding. Regular MRI monitoring is required to detect and manage ARIA.
who Will Benefit from These Treatments?
the benefits of lecanemab and donanemab are not universal. According to Corriere della Sera, these drugs are most effective for patients in the early stages of Alzheimer’s disease who have confirmed amyloid plaque buildup in their brains. This confirmation requires a PET scan or cerebrospinal fluid analysis, adding to the cost and complexity of treatment.
Furthermore, the drugs are not suitable for individuals with advanced Alzheimer’s, as the damage to the brain is already too extensive. Genetic factors, specifically the presence of the APOE4 gene, can also influence both the risk of ARIA and the drug’s effectiveness. Patients with two copies of the APOE4 gene are at higher risk of ARIA and may not be eligible for treatment.
Cost and Access Challenges
A major barrier to access is the high cost of these treatments. Lecanemab currently costs approximately $10,000 per year, not including the costs of PET scans, MRI monitoring, and infusion administration. Donanemab is priced similarly. The Centers for Medicare & Medicaid Services (CMS) has expanded coverage for these drugs, but with specific requirements, including participation in clinical trials and registries to gather real-world evidence.
Access to specialized Alzheimer’s diagnostic centers and infusion facilities is also limited, especially in rural areas. This creates disparities in access to care, potentially exacerbating existing health inequities. The Corriere della Sera article highlights concerns in Italy regarding the availability of these drugs and the infrastructure needed to support their administration.